블로그
- Hormonal Therapy and Cardiovascular Health: Examining the Risk Among Premenopausal Women ... Hormonal Therapy and Cardiovascular Health: Examining the Risk Among Premenopausal Women Diagnosed With diagnosed with hormone receptor–positive breast .......
- Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer Metastatic HER2-Positive Breast Cancer In the phase III DESTINY-Breast09 trial, first-line treatment with trastuzumab plus pertuzumab and a taxane in patients with metastatic HER2-positive breast cancer, reported
- Predictors of receipt of guideline-concordant chemotherapy among ovarian cancer patients in ... iePredictors of receipt of guideline-concordant chemotherapy among ovarian cancer patients in the Kaiser diagnosed with epithelial ovarian cancer in an integrated health system.
- Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation Methods Constitutive and conditional AXL-knockout mice were generated and injected with bleomycin to The expression of AXL and macrophage subtypes in bleomycin-injected mice and patients with idiopathic
- TR #1077 - Cancer models 1077-Ayehunie_2025_Large scale in vitro expansion of primary tumors from metastasis cancer patients with
- Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumor NRAS-mutant tumors are aggressive and associated with poor outcomes. with NRAS wild-type tumors, current therapies for NRAS-mutant cancers are limited.
- A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab The safety profile, pharmacokinetics (PK) and efficacy data for Q702 in combination with pembrolizumab with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers who have progressed on prior
- symptoms and History Poor depth perception: Patients may struggle with judging distances due to binocular vision problems. Asthenopia: Eye strain and headaches associated with prolonged use of the eyes.
- Novel Metastasis Suppressor PI3KC2β Is Mediated by mTORC1 Signaling in Breast Cancer by mTORC1 Signaling in Breast Cancer Abstract HER2 amplification or mutation accounts for 25% of patients with breast cancer that can advance to metastatic disease.
- CA125 levels as a proxy for residual disease in a diverse cohort of epithelial ovarian cancer... CA125 levels as a proxy for residual disease in a diverse cohort of epithelial ovarian cancer patients biomarker for monitoring ovarian cancer progression, but its utility as a biomarker to identify women with